Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 68-77

  Tamura, Kaoru ^a   Wakimoto, Hiroaki ^a   Agarwal, Aayush S ^a   Rabkin, Samuel D ^a   Bhere, Deepak ^a   Martuza, Robert L ^a   Kuroda, Toshihiko ^a,b   Kasmieh, Randa ^a   Shah, Khalid ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Tokorozawa Proctogic Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC VIRUS; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

HUMAN HERPESVIRUS 1; MUS;

EID: 84871925433     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.175     Document Type: Article

References (50)

1. Wen, PY and Kesari, S (2008). Malignant gliomas in adults. N Engl J Med 359:492-507.
2. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.;European Organisation for Research and Treatment of Cancer Brain Tumor andRadiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.(2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med 352: 987-996. (Pubitemid 40349501)
3. Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC et al.;European Organisation for Research and Treatment of Cancer Brain Tumour andRadiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.(2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versusradiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-yearanalysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
4. Aghi, M and Martuza, RL (2005). Oncolytic viral therapies-the clinical experience.Oncogene 24: 7802-7816. (Pubitemid 41670681)
5. Corsten, MF and Shah, K (2008). Therapeutic stem-cells for cancer treatment: hopesand hurdles in tactical warfare. Lancet Oncol 9: 376-384. (Pubitemid 351411654)
6. Johnstone, RW, Frew, AJ and Smyth, MJ (2008). The TRAIL apoptotic pathway incancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
7. Kock, N, Kasmieh, R, Weissleder, R and Shah, K (2007). Tumor therapy mediatedby lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 9: 435-442. (Pubitemid 46799987)
8. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy:a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
9. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al.(2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatmentof malignant glioma: results of a phase I trial. Gene Ther 7: 867-874. (Pubitemid 30303584)
10. Sasportas, LS, Kasmieh, R, Wakimoto, H, Hingtgen, S, van de Water, JA, Mohapatra,G et al. (2009). Assessment of therapeutic efficacy and fate of engineered humanmesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827.
11. Shah, K, Tung, CH, Breakefield, XO and Weissleder, R (2005). In vivo imaging ofS-TRAIL-mediated tumor regression and apoptosis. Mol Ther 11: 926-931. (Pubitemid 40724111)
12. Shah, K, Tung, CH, Yang, K, Weissleder, R and Breakefield, XO (2004). Induciblerelease of TRAIL fusion proteins from a proapoptotic form for tumor therapy. CancerRes 64: 3236-3242. (Pubitemid 38581428)
13. Wakimoto, H, Kesari, S, Farrell, CJ, Curry, WT Jr, Zaupa, C, Aghi, M et al. (2009).Human glioblastoma-derived cancer stem cells: establishment of invasive gliomamodels and treatment with oncolytic herpes simplex virus vectors. Cancer Res69: 3472-3481.
14. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battlebetween oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976. (Pubitemid 41766784)
15. Varghese, S and Rabkin, SD (2002). Oncolytic herpes simplex virus vectors for cancervirotherapy. Cancer Gene Ther 9: 967-978. (Pubitemid 35462560)
16. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuatedmulti-mutated herpes simplex virus-1 for the treatment of malignant gliomas.Nat Med 1: 938-943.
17. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplexvirus vector with enhanced MHC class I presentation and tumor cell killing. Proc NatlAcad Sci USA 98: 6396-6401. (Pubitemid 32488248)
18. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). PhaseIb trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resectionfor recurrent GBM. Mol Ther 17: 199-207.
19. Hoffmann, D and Wildner, O (2007). Comparison of herpes simplex virus-andconditionally replicative adenovirus-based vectors for glioblastoma treatment.Cancer Gene Ther 14: 627-639. (Pubitemid 46912039)
20. LeBlanc, HN and Ashkenazi, A (2003). Apo2L/TRAIL and its death and decoyreceptors. Cell Death Diff 10: 66-75.
21. Wiezorek, J, Holland, P and Graves, J (2010). Death receptor agonists as a targetedtherapy for cancer. Clin Cancer Res 16: 1701-1708.
22. Rozanov, DV, Savinov, AY, Golubkov, VS, Rozanova, OL, Postnova, TI, Sergienko, EA etal. (2009). Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicityin tumor cells. Mol Cancer Ther 8: 1515-1525.
23. Yip, S and Shah, K (2008). Stem-cell based therapies for brain tumors. Curr Opin MolTher 10: 334-342.
24. Bagci-Onder, T, Wakimoto, H, Anderegg, M, Cameron, C and Shah, K (2011). Adual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL inexperimental glioma models. Cancer Res 71: 154-163.
25. Fukuhara, H, Ino, Y, Kuroda, T, Martuza, RL and Todo, T (2005). Triple gene-deletedoncolytic herpes simplex virus vector double-armed with interleukin 18 and solubleB7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res65: 10663-10668. (Pubitemid 41713331)
26. Kuroda, T, Martuza, RL, Todo, T and Rabkin, SD (2006). Flip-Flop HSV-BAC: bacterialartificial chromosome based system for rapid generation of recombinant herpessimplex virus vectors using two independent site-specific recombinases. BMCBiotechnol 6: 40.
27. Yamamoto, S, Deckter, LA, Kasai, K, Chiocca, EA and Saeki, Y (2006). Imagingimmediate-early and strict-late promoter activity during oncolytic herpes simplex virustype 1 infection and replication in tumors. Gene Ther 13: 1731-1736. (Pubitemid 44849038)
28. Han, ZQ, Assenberg, M, Liu, BL, Wang, YB, Simpson, G, Thomas, S et al. (2007).Development of a second-generation oncolytic Herpes simplex virus expressingTNFalpha for cancer therapy. J Gene Med 9: 99-106. (Pubitemid 46444487)
29. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al. (2007).Effect of tumor microenvironment modulation on the efficacy of oncolytic virustherapy. J Natl Cancer Inst 99: 1768-1781. (Pubitemid 351767207)
30. Kirn, D, Martuza, RL and Zwiebel, J (2001). Replication-selective virotherapy forcancer: Biological principles, risk management and future directions. Nat Med7: 781-787. (Pubitemid 32691631)
31. Markert, E, Siebolts, U, Odenthal, M, Kreuzer, KA and Wickenhauser, C (2009). Highdiagnostic value of morphologic examination and molecular analysis of bone marrowbiopsies in a case of BCR-ABL+ CML with clusters of blasts. Int J Hematol 89: 294-297.
32. Corsten, MF, Miranda, R, Kasmieh, R, Krichevsky, AM, Weissleder, R and Shah,K (2007). MicroRNA-21 knockdown disrupts glioma growth in vivo and displayssynergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.Cancer Res 67: 8994-9000. (Pubitemid 47535880)
33. Shah, K, Hingtgen, S, Kasmieh, R, Figueiredo, JL, Garcia-Garcia, E, Martinez-Serrano, Aet al. (2008). Bimodal viral vectors and in vivo imaging reveal the fate of human neuralstem cells in experimental glioma model. J Neurosci 28: 4406-4413.
34. Shah, K, Tang, Y, Breakefield, X and Weissleder, R (2003). Real-time imaging of TRAILinducedapoptosis of glioma tumors in vivo. Oncogene 22: 6865-6872. (Pubitemid 37386686)
35. Rieger, J, Frank, B, Weller, M and Wick, W (2007). Mechanisms of resistance of humanglioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell PhysiolBiochem 20: 23-34. (Pubitemid 46956809)
36. Todo, T (2008). "Armed" oncolytic herpes simplex viruses for brain tumor therapy.Cell Adh Migr 2: 208-213.
37. Leopardi, R, Van Sant, C and Roizman, B (1997). The herpes simplex virus 1 proteinkinase US3 is required for protection from apoptosis induced by the virus. Proc NatlAcad Sci USA 94: 7891-7896.
38. Leopardi, R and Roizman, B (1996). The herpes simplex virus major regulatory proteinICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA93: 9583-9587. (Pubitemid 26296651)
39. Perkins, D, Gyure, KA, Pereira, EF and Aurelian, L (2003). Herpes simplex virus type1-induced encephalitis has an apoptotic component associated with activation ofc-Jun N-terminal kinase. J Neurovirol 9: 101-111. (Pubitemid 36372550)
40. Walsh, D and Mohr, I (2004). Phosphorylation of eIF4E by Mnk-1 enhances HSV-1translation and replication in quiescent cells. Genes Dev 18: 660-672. (Pubitemid 38489934)
41. Mebratu, Y and Tesfaigzi, Y (2009). How ERK1/2 activation controls cell proliferationand cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175.
42. Allan, LA, Morrice, N, Brady, S, Magee, G, Pathak, S and Clarke, PR (2003). Inhibitionof caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647-654. (Pubitemid 36818087)
43. Holmström, TH, Schmitz, I, Söderström, TS, Poukkula, M, Johnson, VL, Chow, SC et al.(2000). MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosisdownstream of DISC assembly. EMBO J 19: 5418-5428.
44. Erhardt, P, Schremser, EJ and Cooper, GM (1999). B-Raf inhibits programmed celldeath downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315. (Pubitemid 29339890)
45. Jacobson, MD, Weil, M and Raff, MC (1997). Programmed cell death in animaldevelopment. Cell 88: 347-354.
46. Tashker, JS, Olson, M and Kornbluth, S (2002). Post-cytochrome C protection fromapoptosis conferred by a MAPK pathway in Xenopus egg extracts. Mol Biol Cell13: 393-401. (Pubitemid 34165069)
47. Xia, Z, Dickens, M, Raingeaud, J, Davis, RJ and Greenberg, ME (1995).Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science270: 1326-1331.
48. Wohlfahrt, ME, Beard, BC, Lieber, A and Kiem, HP (2007). A capsid-modified,conditionally replicating oncolytic adenovirus vector expressing TRAILLeads to enhanced cancer cell killing in human glioblastoma models. Cancer Res67: 8783-8790. (Pubitemid 47437454)
49. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011).Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus inhumans. Nature 477: 99-102.
50. Saeki, Y, Ichikawa, T, Saeki, A, Chiocca, EA, Tobler, K, Ackermann, M et al. (1998).Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome inEscherichia coli: rescue of replication-competent virus progeny and packaging ofamplicon vectors. Hum Gene Ther 9: 2787-2794. (Pubitemid 29027021)